7598-70-1

Usage

Uses

Used in Organic Synthesis:
Diethyl (4-nitrobenzyl)propanedioate is used as a reagent in organic synthesis for the preparation of various organic compounds. Its unique structure allows for versatile reactions and the formation of a wide range of products.
Used in Pharmaceutical Production:
Diethyl (4-nitrobenzyl)propanedioate is used as an intermediate in the production of pharmaceuticals. Its presence in the synthesis process contributes to the development of new drugs and medicines.
Used in Medicinal Chemistry and Drug Discovery:
Diethyl (4-nitrobenzyl)propanedioate is used as a precursor in the synthesis of biologically active molecules. Its potential pharmacological activities and interactions with biological systems make it a valuable component in the discovery and development of new therapeutic agents.
Used in the Synthesis of Biologically Active Molecules:
Diethyl (4-nitrobenzyl)propanedioate is used as a precursor in the synthesis of biologically active molecules, which can have various applications in the medical and pharmaceutical fields. Its ability to contribute to the creation of such molecules highlights its importance in advancing scientific research and innovation.

Upstream product

• 996-82-7 sodium diethylmalonate 
• 100-14-1 4-nitrobenzyl chloride 
• 105-53-3 diethyl malonate 
• 607-81-8 diethyl 2-benzylmalonate 
• 22399-00-4 diethyl 4-nitrobenzylidene malonate 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 555-16-8 4-nitrobenzaldehdye 

Downstream Products

• 128924-89-0 12-(4-Nitrobenzyl)-1,4,7,10-tetraazacyclotridecane-11,13-dione 
• 419563-69-2 diethyl 2-(benzyloxymethyl)-2-[(4-nitrophenyl)methyl]propanedioate 
• 162898-33-1 13-(4-nitrobenzyl)-1,4,8,11-tetraazacyclotetradecane 
• 693785-40-9 2-(4-nitrobenzyl)-1,3-dibromopropane 
• 694527-20-3 cis-2-(4-nitrobenzyl)decahydro-3a,5a,8a,10a-tetraazapyrene 
• 693785-41-0 cis-10b,10c-dimethyl-2t-(4-nitrobenzyl)decahydro-3a,5a,8a,10a-tetraazapyrene 
• 1211547-69-1 C₂₄H₃₇NO₇Si 
• 134439-25-1 2-[(4-nitrophenyl)methyl]propan-1,3-diol bis(4-methylbenzenesulfonate) 
• 1276543-48-6 4,11-N,N'-bis(carbo-tert-butoxymethyl)-16-(4-nitrobenzyl)-1,4,8,11-tetraazabicyclo[6.6.3]heptadecane 
• 1276543-49-7 4,11-bis-(carbo-tert-butoxymethyl)-16-(4-aminobenzyl)-1,4,8,11-tetraazabicyclo[ 6.6.3]heptadecane 
• 1276543-57-7 4,10-bis-(carbo-tert-butoxymethyl)-14-(4-nitrobenzyl)-1,4,7,10-tetraazabicyclo[5. 5.3]pentadecane 
• 1276543-58-8 4,10-bis-(carbo-tert-butoxymethyl)-14-(4-aminobenzyl)-1,4,7,10-tetraazabicyclo[ 5.5.3]pentadecane 
• 1276543-50-0 4,11-bis-(carboxymethyl)-16-(4-aminobenzyl)-1,4,8,11-tetraazabicyclo[6.6.3]heptadecane 
• 1278402-25-7 C₅₂H₇₈N₁₄O₁₂S 

Relevant academic research and scientific papers

Evaluation of the Tetrakis(3-Hydroxy-4-Pyridinone) Ligand THPN with Zirconium(IV): Thermodynamic Solution Studies, Bifunctionalization, and in Vivo Assessment of Macromolecular89Zr-THPN-Conjugates

Zirconium-89 (89Zr) is a suitable radionuclide for positron-emission tomography (PET) of long-circulating targeting vectors such as monoclonal antibodies (mAbs). Due to stability concerns for the most widely used 89Zr-chelating agent

Chemoselective Reduction of Nitrobenzylidene Malonic Diester by an NADH Model

The carbon-carbon double bond or the nitro group of nitrobenzylidene malonic diethyl ester has been reduced selectively with Hantzsch ester using a metal ion catalyst or by sensitized photoirradiation, providing evidence of a one step hydride transfer and

A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89

Herein we report a new high-denticity chelator based on the iron siderophore desferrioxamine (DFO). Our new chelator-DFO2-is acyclic and was designed and synthesized with the purpose of improving the coordination chemistry and radiolabeling performance with radioactive zirconium-89. The radionuclide zirconium-89 ([89Zr]Zr4+) has found wide use for positron emission tomography (PET) imaging when it is coupled with proteins, antibodies, and nanoparticles. DFO2 has a potential coordination number of 12, which uniquely positions this chelator for binding large, high-valent, and oxophilic metal ions. Following synthesis of the DFO2 chelator and the [natZr]Zr-(DFO2) complex we performed density functional theory calculations to study its coordination sphere, followed by zirconium-89 radiolabeling experiments for comparisons with the "gold standard"chelator DFO. DFO (CN 6) can coordinate with zirconium in a hexadentate fashion, leaving two open coordination sites where water is thought to coordinate (total CN 8). DFO2 (potential CN 12, dodecadentate) can saturate the coordination sphere of zirconium with four hydroxamate groups (CN 8), with no room left for water to directly coordinate, and only binds a single atom of zirconium per chelate. Following quantitative radiolabeling with zirconium-89, the preformed [89Zr]Zr-(DFO) and [89Zr]Zr-(DFO2) radiometal-chelate complexes were subjected to a battery of in vitro stability challenges, including human blood serum, apo-transferrin, serum albumin, iron, hydroxyapatite, and EDTA. One objective of these stability challenges was to determine if the increased denticity of DFO2 over that of DFO imparted improved complex stability, and another was to determine which of these assays is most relevant to perform with future chelators. In all of the assays DFO2 showed superior stability with zirconium-89, except for the iron challenge, where both DFO2 and DFO were identical. Substantial differences in stability were observed for human blood serum using a precipitation method of analysis, apo-transferrin, hydroxyapatite, and EDTA challenges. These results suggest that DFO2 is a promising next-generation scaffold for zirconium-89 chelators and holds promise for radiochemistry with even larger radionuclides, which we anticipate will expand the utility of DFO2 into theranostic applications.

Programmed Sequential Additions to Halogenated Mucononitriles

Dihalomucononitriles were synthesized and their reactivity evaluated to assess their ability to function as linchpin reagents. Bis(2-chloroacrylonitrile) and bis(2-bromoacrylonitrile) were synthesized from 2,1,3-benzothiadiazole and undergo conjugate addition/elimination reactions with both nitrogen (40-95% yield) and carbon nucleophiles (72-93% yield). Secondary amines undergo monosubstitutions, while carbon nucleophiles are added twice. The sequence of addition of the nucleophiles could be controlled to give mixed addition products. The multicomponent coupling products could then be converted to natural product like motifs using intramolecular cyclization reactions.

Environmentally benign nucleophilic substitution reaction of arylalkyl halides in water using CTAB as the inverse phase transfer catalyst

An environmentally benign, practically scalable and highly selective C-arylalkylation of active methylene compounds is developed using CTAB as the inverse phase transfer catalyst in water. The methodology developed is elaborated into the one-pot synthesis of quinoline derivatives and also applicable to the regioselective N-aralkyl of 2-pyridones.

Aryltrifluoromethylative cyclization of unactivated alkenes by the use of PhICF3Cl under catalyst-free conditions

A concise and catalyst-free aryltrifluoromethylative cyclization of unactivated alkenes has been developed herein. The use of PhICF3Cl as a powerful trifluoromethylating agent allows easy transformations. A set of trifluoroethylated carbocycles and aza-hereocycles were efficiently synthesized in good yield and selectivity. A broad substrate scope, mild reaction conditions, and easy operation would make this method well-suited for applications.

Propylene cross-bridged macrocyclic bifunctional chelator: A new design for facile bioconjugation and robust 64cu complex stability

The first macrocyclic bifunctional chelator incorporating propylene cross-bridge was efficiently synthesized from cyclam in seven steps. After the introduction of an extra functional group for facile conjugation onto the propylene cross-bridge, the two carboxylic acid pendants could contribute to strong coordination of Cu(II) ions, leading to a robust Cu complex. The cyclic RGD peptide conjugate of PCB-TE2A-NCS was prepared and successfully radiolabeled with 64Cu ion. The radiolabeled peptide conjugate was evaluated in vivo through a biodistribution study and animal PET imaging to demonstrate high tumor uptake with low background.

4-alkyloxyimino derivatives of uridine-5′-triphosphate: Distal modification of potent agonists as a strategy for molecular probes of P2Y 2, P2Y4, and P2Y6 receptors

Extended N4-(3-arylpropyl)oxy derivatives of uridine-5′-triphosphate were synthesized and potently stimulated phospholipase C stimulation in astrocytoma cells expressing G protein-coupled human (h) P2Y receptors (P2YRs) activated by UTP (P2Y2/4R) or UDP (P2Y6R). The potent P2Y4R-selective N4-(3- phenylpropyl)oxy agonist was phenyl ring-substituted or replaced with terminal heterocyclic or naphthyl rings with retention of P2YR potency. This broad tolerance for steric bulk in a distal region was not observed for dinucleoside tetraphosphate agonists with both nucleobases substituted. The potent N 4-(3-(4-methoxyphenyl)-propyl)oxy analogue 19 (EC50: P2Y2R, 47 nM; P2Y4R, 23 nM) was functionalized for chain extension using click tethering of fluorophores as prosthetic groups. The BODIPY 630/650 conjugate 28 (MRS4162) exhibited EC50 values of 70, 66, and 23 nM at the hP2Y2/4/6Rs, respectively, and specifically labeled cells expressing the P2Y6R. Thus, an extended N4-(3- arylpropyl)oxy group accessed a structurally permissive region on three G q-coupled P2YRs, and potency and selectivity were modulated by distal structural changes. This freedom of substitution was utilized to design of a pan-agonist fluorescent probe of a subset of uracil nucleotide-activated hP2YRs.

NOVEL TETRA-AZA MACROCYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF

Provided are a cross-bridged tetraaza macrocyclic compound of a novel structure that can be used, for example, as a contrast agent for diagnostic imaging or a radiopharmaceutical and a method for preparing the same. The disclosed tetraaza macrocyclic comp

NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF

Provided are a cross-bridged tetraaza macrocyclic compound of a novel structure that can be used, for example, as a contrast agent for diagnostic imaging or a radiopharmaceutical and a method for preparing the same. The disclosed tetraaza macrocyclic compound is able to form a stable metal complex at a lower temperature and allows easy conjugation with a bioactive substance or a chemically active substance, when compared to the existing cross-bridged tetraaza macrocyclic compounds.